SAN DIEGO--(BUSINESS WIRE)--LATITUDE Pharmaceuticals, Inc. (LPI), a San Diego-based drug formulation developer, announced today that it has initiated four additional collaborative programs for its Phospholipid Gel (PG) Depot drug delivery technology. The programs are designed to provide sustained delivery of small and large therapeutic molecules up to 7 days following a single subcutaneous or intramuscular injection. The new studies bring the total to eleven collaborations that are applying the PG Depot to deliver small molecule, peptide, and protein drugs across a broad spectrum of therapeutic applications.
